Sponsored by
I usually do not list trials at an individual brain tumor center, but this one is special. These are 4 of my favorite trials, all done at one medical center, and they are also certified to use the Optune treatment as well. For more information, look at virtualtrials.com click on LEARN ABOUT then Tocagen, then Learn About and Vaccines.
These trials are now being offered at JFK Brain Tumor Center in Edison, NJ.
A Phase 1 Trial of ICT121 (brain tumor vaccine) in the treatment of first recurrent glioblastoma. *This trial requires gross total resection or near total with less than one cubic centimeter of residual disease. Patient's need to be HLAA2 positive, which will be tested at screening.
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended Release 5FC.
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent High Grade Glioma and Followed
by Treatment with Toca FC, Extended?Release 5?FC
A Phase 3 Clinical Trial Evaluating DCVax-L, Autologous Dendritic Cell Pulsed with Tumor Lysate Antigen for the Treatment of Newly Diagnosed Glioblastoma. * This trial needs to be screened prior to resection as the vaccine is made from the patients own tumor tissue.
In addition, I am a Certified Provider of the Novo-TTF 100A Device for Recurrent Malignant Glioblastoma.
Thank you for your help,
Joseph C. Landolfi, D.O.
Chief of Neurology
JFK Neuroscience
Director of Neuro-oncology
Medical Director, Gamma Knife Program
JFK Brain Tumor Center
Chairman, Institutional Review Board
JFK Health
Medical Director of Neuro-oncology
Meridian Health
Professor of Neurology
Seton Hall School of Health and Medical Sciences
732-321-7950-office phone